2-phenyl-[1,2,4]triazolo[1,5-a]pyridine compounds, nitrogen oxides thereof and uses thereof
By developing 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine compounds as AhR agonists, the problems of low selectivity and major side effects in existing psoriasis treatments have been solved. Effective treatment in psoriasis and reduced recurrence rates are achieved.
Patent Information
- Application Number
- CN202210063906.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-01-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-01-20
AI Technical Summary
Existing psoriasis treatment drugs have low selectivity, large side effects, difficulty in long-term use and high recurrence rates, especially in large-area smear and systematic treatment, and lack effective targeted treatment options.
A class of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine compounds and their nitrogen oxides were developed as AhR agonists for restoration of Th17/22 and Treg cells. Immune balance, thus treating psoriasis.
This compound significantly activates the AhR signaling pathway in human line cells, induces CYP1A1 transcription, and shows significant anti-psoriatic effects in mouse models, providing a new targeted therapeutic option that reduces side effects and recurrence of the drug Rate.
Smart Images

Figure CN116514801B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of chemical medicine, and specifically relates to a class of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine compounds, their nitrogen oxides, and a preparation method and use thereof in medicine. Background Art
[0002] Psoriasis, also known as psoriasis, is an immune-mediated chronic, recurrent, inflammatory, systemic disease induced by the combined effects of genetics and the environment. The global prevalence is about 2%. Its typical clinical manifestations are scaly erythema or plaques, which are localized or widely distributed, non-infectious, difficult to treat, and often lifelong. Moderate to severe patients may even suffer from hyperlipidemia, diabetes, metabolic syndrome, hypertension, mood disorders, etc. Common topical drugs for psoriasis include emollients, moisturizers, vitamin D3 derivatives, retinoic acid, glucocorticoids, calcineurin inhibitors, anti-human interleukin 8 monoclonal antibodies and tar preparations, etc., which are not suitable for large-area application, have large side effects with long-term use, and relapse after discontinuation, and are difficult to treat after relapse. Systemic treatment drugs include methotrexate, cyclosporine, retinoic acid and biological agents, which are mostly used for patients with large areas and moderate to severe psoriasis, but have large side effects and low selectivity. The development of targeted drugs has become an opportunity and challenge for the treatment of psoriasis.
[0003] The etiology of psoriasis involves multiple factors such as genetics, immunity, and environment. Through an immune response mediated mainly by T lymphocytes and involving multiple immune cells, keratinocytes overproliferate or synovial cells and chondrocytes in the joints become inflamed. Current studies have found that the IL-23 / Th17 axis plays an important role in the pathogenesis of psoriasis. Dendritic cells and macrophages in the psoriasis dermis produce IL-23, which induces Th17 cell activation and releases inflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-6, and TNF-α. Inflammatory factors act on keratinocytes, leading to typical pathological changes of psoriasis such as epidermal hyperplasia, acanthosis, and hyperkeratosis. In the inflammatory microenvironment of the skin, keratinocytes can produce more inflammatory factors, forming an IL-23 / Th17 positive feedback loop, amplifying and exacerbating the chronic inflammatory pathological process of psoriasis. Aryl hydrocarbon receptor (AhR) mainly regulates the immune balance of Th17 / 22 and Treg cells, and its signaling pathway plays an important role in the IL-23 / Th17 axis.
[0004] AhR is a ligand-activated transcription factor. Human AhR is mainly expressed in the skin, lungs, thymus, kidneys, and liver. In its unactivated form, AhR usually forms a multiprotein complex with heat shock protein 90 (Hsp90), p23, X-associated protein 2 (XAP2), and AhR-associated protein 9 (ARA9) in the cytoplasm. The classical signaling pathway is that when AhR binds to a ligand and is activated, its conformation changes and the nuclear localization signal sequence is exposed. The receptor-ligand complex translocates to the nucleus and forms a heterodimer with the AhR nuclear translocator (ARNT) in the nucleus. The AhR / ARNT complex binds to the heterologous biological response element of the target gene promoter and activates the expression of target genes including cytochrome P450 enzymes (CYP1A1, CYP1A2, CYP1B1), thereby participating in many important physiological processes, including detoxification and immunity. AhR / ARNT signaling also activates the OVO-like 1 (OVOL1) transcription factor, thereby upregulating the expression of filaggrin (FLG) and loricrin (LOR), while upregulating the expression of integrin (IVL) in an OVOL1-independent manner, ultimately manifesting AhR / ARNT signaling as accelerating epidermal terminal differentiation and enhancing the repair of barrier damage.
[0005] Therefore, developing agonists targeting AhR and restoring the immune balance of Th17 / 22 and Treg cells will play an important role in the treatment of psoriasis. Summary of the invention
[0006] The object of the present invention is to provide a class of compounds, nitrogen oxides and salts thereof that can be used to prepare agonists targeting AhR.
[0007] The present invention first provides a compound represented by formula I or a pharmaceutically acceptable salt thereof, the structure of which is as follows:
[0008]
[0009] R 1 ~R 4 are independently selected from H, halogen, cyano, halogen-substituted or unsubstituted C1-C8 alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, or R 1 and R 2 Together with the main ring, it forms a 6-membered aromatic ring or a 5-membered heterocyclic ring, or R 2 and R 3 Together with the main ring, it forms a 6-membered aromatic ring or a 5-membered heterocyclic ring, or R 3 and R 4 It forms a 6-membered aromatic ring or a 5-membered heterocyclic ring with the main ring;
[0010] R 1 ~R4 In the above, the 5- to 10-membered heteroaryl group contains 1 to 3 heteroatoms selected from N, S, and O; the ring forming a 5-membered heterocyclic ring with the main ring contains 1 to 2 heteroatoms selected from N, S, and O;
[0011] is selected from a substituted or unsubstituted 6- to 10-membered aromatic ring, a substituted or unsubstituted 5- to 10-membered heteroaromatic ring, wherein the 5- to 10-membered heteroaromatic ring contains 1 to 2 heteroatoms, and the heteroatoms are N, S, or O;
[0012] wherein the substituents of the substituted 6-10 membered aromatic ring and the substituted 5-10 membered heteroaromatic ring are independently selected from halogen, nitro, cyano, halogen substituted or unsubstituted C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkoxycarbonyl, At least one of;
[0013] R 9 Selected from C1~C8 alkyl.
[0014] Among the above nitrogen oxides, R 1 ~R 4 Independently selected from H, halogen, cyano, halogen substituted or unsubstituted C1-C6 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl; the 5-10 membered heteroaryl contains 1-2 heteroatoms selected from N, S, and O.
[0015] Preferably, among the above nitrogen oxides, R 1 ~R 4 Independently selected from H, halogen, cyano, fluorine substituted or unsubstituted C1-C4 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl.
[0016] More preferably, among the above nitrogen oxides, R 1 ~R 4 Independently selected from H, F, Cl, Br, cyano, methyl, trifluoromethyl, 6-membered aryl, 5-membered heteroaryl; the 5-membered heteroaryl contains 1 heteroatom, and the heteroatom is selected from N, S, and O.
[0017] Among the above nitrogen oxides, R 1 , R 2 , R 3 , R 4 When not in exchange with the main ring, R 1 ~R 4 At least three of them are H.
[0018] Among the above nitrogen oxides, It is selected from a substituted or unsubstituted 6- to 10-membered aromatic ring and a substituted or unsubstituted 5- to 10-membered heteroaromatic ring, wherein the 5- to 10-membered heteroaromatic ring contains one heteroatom, and the heteroatom is N, S, or O.
[0019] Preferably, among the above nitrogen oxides, In the above, the 6- to 10-membered aromatic ring is selected from benzene and naphthalene, and the 5- to 10-membered heteroaromatic ring is selected from furan, thiophene, pyrrole and pyridine.
[0020] Among the above nitrogen oxides, wherein the substituents of the substituted 6-10 membered aromatic ring and the substituted 5-10 membered heteroaromatic ring are selected from halogen, nitro, cyano, halogen substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, At least one of R 9 Selected from C1~C6 alkyl.
[0021] Preferably, among the above nitrogen oxides, wherein the substituents of the substituted 6-10 membered aromatic ring and the substituted 5-10 membered heteroaromatic ring are selected from halogen, nitro, cyano, fluorine-substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkoxycarbonyl, At least one of R 9 Selected from C1~C4 alkyl.
[0022] More preferably, among the above nitrogen oxides, wherein the substituents of the substituted 6- to 10-membered aromatic ring and the substituted 5- to 10-membered heteroaromatic ring are selected from F, Cl, Br, nitro, cyano, methyl, trifluoromethyl, methoxy, methoxycarbonyl, At least one of .
[0023] Most preferably, among the above nitrogen oxides, Selected from
[0024] The present invention also provides some specific compounds among the above nitrogen oxides, and their structures are as follows:
[0025]
[0026]
[0027] The present invention also provides a method for preparing the above-mentioned 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine nitrogen oxide derivatives of formula I, and the synthetic route thereof is:
[0028]
[0029] Process conditions of each step: a, hydroxylamine hydrochloride, potassium acetate, ethanol, 80°C, 1-2h; b, NCS, DMF, rt, 1-2h; c, dimethyl sulfide, NCS, sodium methoxide, dichloromethane, -20°C-25°C, 6h; d, dimethyl sulfide, NCS, 0°C, 2h; e, triethylamine, rt, 24h;
[0030] The present invention also provides a compound represented by Formula II or a pharmaceutically acceptable salt thereof, the structure of which is as follows:
[0031]
[0032] R 5 ~R 8 are independently selected from H, halogen, cyano, halogen-substituted or unsubstituted C1-C8 alkyl, 6-10-membered aryl, 5-10-membered heteroaryl, or R 5 and R 6 Together with the main ring, it forms a 6-membered aromatic ring or a 5-membered heterocyclic ring, or R 6 and R 7 Together with the main ring, it forms a 6-membered aromatic ring or a 5-membered heterocyclic ring, or R 7 and R 8 It forms a 6-membered aromatic ring or a 5-membered heterocyclic ring with the main ring;
[0033] R 5 ~R 8 In the above, the 5- to 10-membered heteroaryl group contains 1 to 3 heteroatoms selected from N, S, and O; the ring forming a 5-membered heterocyclic ring with the main ring contains 1 to 2 heteroatoms selected from N, S, and O;
[0034] is selected from a substituted or unsubstituted 6- to 10-membered aromatic ring, a substituted or unsubstituted 5- to 10-membered heteroaromatic ring, wherein the 5- to 10-membered heteroaromatic ring contains 1 to 2 heteroatoms, and the heteroatoms are N, S, or O;
[0035] wherein the substituents of the substituted 6-10 membered aromatic ring and the substituted 5-10 membered heteroaromatic ring are independently selected from halogen, nitro, cyano, halogen substituted or unsubstituted C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkoxycarbonyl, At least one of R 10 Selected from C1~C8 alkyl.
[0036] Among them, in the above compounds, R 5 ~R 8 Independently selected from H, halogen, cyano, halogen substituted or unsubstituted C1-C6 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl; the 5-10 membered heteroaryl contains 1-2 heteroatoms selected from N, S, and O.
[0037] Preferably, in the above compounds, R 5 ~R 8 Independently selected from H, halogen, cyano, fluorine substituted or unsubstituted C1-C4 alkyl, 6-10 membered aryl, 5-10 membered heteroaryl.
[0038] More preferably, in the above compound, R 5 ~R 8 Independently selected from H, F, Cl, Br, cyano, methyl, trifluoromethyl, 6-membered aryl, 5-membered heteroaryl; the 5-membered heteroaryl contains 1 heteroatom, and the heteroatom is selected from N, S, and O.
[0039] Among them, in the above compounds, R 5 , R 6 , R 7 , R 8 When not in exchange with the main ring, R 5 ~R 8 At least three of them are H.
[0040] Among the above compounds, It is selected from a substituted or unsubstituted 6- to 10-membered aromatic ring and a substituted or unsubstituted 5- to 10-membered heteroaromatic ring, wherein the 5- to 10-membered heteroaromatic ring contains one heteroatom, and the heteroatom is N, S, or O.
[0041] Preferably, among the above compounds, In the above, the 6- to 10-membered aromatic ring is selected from benzene and naphthalene, and the 5- to 10-membered heteroaromatic ring is selected from furan, thiophene, pyrrole and pyridine.
[0042] Among the above compounds, wherein the substituents of the substituted 6-10 membered aromatic ring and the substituted 5-10 membered heteroaromatic ring are selected from halogen, nitro, cyano, halogen substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, At least one of R 10 Selected from C1~C6 alkyl.
[0043] Preferably, among the above compounds, wherein the substituents of the substituted 6-10 membered aromatic ring and the substituted 5-10 membered heteroaromatic ring are selected from halogen, nitro, cyano, fluorine-substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkoxycarbonyl, At least one of R 10 Selected from C1~C4 alkyl.
[0044] More preferably, among the above compounds, wherein the substituents of the substituted 6- to 10-membered aromatic ring and the substituted 5- to 10-membered heteroaromatic ring are selected from F, Cl, Br, nitro, cyano, methyl, trifluoromethyl, methoxy, methoxycarbonyl, At least one of .
[0045] Most preferably, among the above compounds, Selected from
[0046] The present invention also provides some specific compounds among the above compounds, and their structures are as follows:
[0047]
[0048] The present invention also provides a method for preparing the above-mentioned 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula II, and the synthetic route thereof is:
[0049]
[0050] Process conditions of each step: f, NaH, DMF, 0-25°C, 12h; g, KI, I 2 , K 2 CO 3 , 100℃, 4-6h.
[0051] The present invention also provides a class of pharmaceutical compositions, which are composed of the above-mentioned nitrogen oxide of formula I or a pharmaceutically acceptable salt thereof, the above-mentioned compound of formula II or a pharmaceutically acceptable salt thereof as active ingredients, and pharmaceutically acceptable auxiliary ingredients.
[0052] The present invention also provides the use of the above-mentioned nitrogen oxide of formula I or its pharmaceutically acceptable salt, the above-mentioned compound of formula II or its pharmaceutically acceptable salt as an active ingredient, and the above-mentioned pharmaceutical composition in the preparation of an AHR agonist.
[0053] The present invention also provides the use of the above-mentioned nitrogen oxide of formula I or its pharmaceutically acceptable salt, the above-mentioned compound of formula II or its pharmaceutically acceptable salt as an active ingredient, and the above-mentioned pharmaceutical composition in the preparation of a drug for treating psoriasis.
[0054] Beneficial effects of the present invention:
[0055] The present invention provides a class of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine compounds and nitrogen oxide derivatives thereof, which can be used to prepare AHR agonists and provide a new option for preparing drugs for treating psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1This is the activity curve of compound 12a and the positive drug Tapinarf.
[0057] Figure 2 This is the transcription diagram of compound 12a inducing CYP1A1.
[0058] Figure 3 Compound 12a induces AhR enrichment in the cell nucleus.
[0059] Figure 4 This is a graph showing the anti-psoriasis effect of oral compound 12a.
[0060] Figure 5 This is a diagram showing the anti-psoriasis effect of topical compound 12a. DETAILED DESCRIPTION
[0061] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0062] Example 1: 2-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0063]
[0064] The first step: 4-methoxybenzaldehyde (1.36g, 10mmol), hydroxylamine hydrochloride (0.84g, 12mmol), potassium acetate (1.18g, 12mmol) were added to a 100ml eggplant-shaped bottle, 60ml of ethanol was added as solvent, and the mixture was reacted at 80°C for 1h, and detected by thin layer chromatography. After the reaction was complete, the reaction was cooled to room temperature, and the solvent was removed by vacuum distillation. The residue was dissolved in ethyl acetate, washed with water, washed with saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The organic phase was vacuum distilled, and the residue was the target intermediate, i.e., 4-methoxybenzaldehyde oxime, which did not need to be purified and was directly used for the next step of reaction.
[0065] Step 2: The intermediate obtained in the first step was dissolved in DMF, NCS (1.1 eq) was added, and the reaction was carried out at room temperature for 1 h. The reaction was detected by thin layer chromatography. After the reaction was complete, a large amount of water was added, and the mixture was extracted with ethyl acetate (three times). The organic phases were combined, dried over anhydrous sodium sulfate, and evaporated under pressure. The residue was separated by column chromatography to obtain the target product, i.e., N-hydroxy-4-methoxybenzoimidoyl chloride.
[0066] Step 3: Dissolve 2-aminopyridine (1 eq) in dichloromethane and stir at -20°C. Dissolve dimethyl sulfide (1.1 eq) in dichloromethane and slowly add dropwise. Add NCS (1 eq, dissolved in dichloromethane) and continue stirring at -20°C for 1 hour. Transfer the reaction system to room temperature and continue stirring for 1 hour. Add sodium methoxide solution and continue stirring for 10 minutes. Add water and continue stirring for 4 hours. Separate and collect the organic phase. Extract the aqueous phase with dichloromethane. Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate. Recrystallize the residue with ether and filter. The solid is the target product, i.e., 1,1-dimethyl-N-(pyridin-2-yl)-14-sulfonamide.
[0067] Step 4: dissolve m-chloroperbenzoic acid (3 eq) in dry dichloromethane, dissolve 1,1-dimethyl-N-(pyridin-2-yl)-14-sulfonamide (1 eq) in dichloromethane, add all at once at 0°C, react at 0°C for 1.5 hours, add saturated sodium carbonate solution, separate, collect the organic phase, extract the aqueous phase with dichloromethane, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate, and recrystallize from ethanol to obtain the target product, i.e., 2-nitrosopyridine.
[0068] Step 5: Dissolve N-hydroxy-4-methoxybenzoimidoyl chloride (1 eq) and 2-nitrosopyridine (1 eq) in dichloromethane, add triethylamine, stir at room temperature for 24 h, and detect by TLC. After the reaction is complete, extract with saturated sodium bicarbonate aqueous solution, collect the organic phase, distill the organic phase under reduced pressure, separate the residue by column chromatography, and concentrate to obtain the final product 8a, i.e., 2-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-oxide. 1 H NMR (400 MHz, DMSO-d 6 )δ8.77(d,J=6.9Hz,1H),8.61(d,J=9.0Hz,2H),7.86(d,J=9.0Hz,1H),7.7 4–7.68(m,1H),7.35(t,J=6.9Hz,1H),7.17(d,J=9.0Hz,2H),3.86(s,3H).
[0069] Example 2: 2-(Pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0070]
[0071] The synthesis method of compound 8b is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6)δ9.73(s,1H),8.97(d,J=8.1Hz,1H),8.84(d,J=6.9Hz,1H),8.75(d,J=4.7Hz,1H),7.94 (d,J=9.0Hz,1H),7.81–7.73(m,1H),7.66(dd,J=8.0,4.9Hz,1H),7.41(t,J=6.9Hz,1H).
[0072] Example 3: 2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0073]
[0074] The synthesis method of compound 8c is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ8.81(dd,J=6.9,1.4Hz,1H),8.64–8.57(m,2H),7.90(dd,J=9.1,1.3Hz,1H),7 .87–7.79(m,2H),7.75(ddd,J=8.6,6.9,1.2Hz,1H),7.38(td,J=6.9,1.1Hz,1H).
[0075] Example 4: 2-(1H-indol-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0076]
[0077] The synthesis method of compound 8d is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ11.95(s,1H),8.79(s,1H),8.77(d,J=6.8Hz,1H),8.50(dd,J=7.0,2.0Hz,1H),7.89(d,J=8.9Hz,1H),7.7 0(ddd,J=8.7,7.0,1.3Hz,1H),7.59–7.53(m,1H),7.35(td,J=6.9,1.1Hz,1H),7.25(pd,J=7.1,1.5Hz,2H).
[0078] Example 5: 6-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0079]
[0080] The synthesis method of compound 8e is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.07(s,1H),8.56(d,J=8.6Hz,2H),7.86(d,J=1.1Hz,2H),7.84(d,J=8.6Hz,2H).
[0081] Example 6: 2-(4-bromophenyl)-6-chloro-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0082]
[0083] The synthesis method of compound 8f is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ8.73(d,J=1.3Hz,1H),8.59(d,J=8.7Hz,2H),7.70(d,J=8.7Hz,2H),7.65(d,J=9.4Hz,1H),7.54(dd,J=9.5,1.9Hz,1H).
[0084] Example 7: 6-Chloro-2-(4-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0085]
[0086] The synthesis method of compound 8g is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ8.73(s,1H),8.65(d,J=7.3Hz,2H),7.64(s,1H),7.54(d,J=7.9Hz,3H).
[0087] Example 8: 6-Chloro-2-(6-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0088]
[0089] The synthesis method of compound 8h is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6)δ9.50(d,J=2.4Hz,1H),9.17(ddd,J=8.7,7.6,2.4Hz,1H),8.74(dd,J=2.0,0.9Hz,1H) ,7.69(dd,J=9.5,0.9Hz,1H),7.58(dd,J=9.5,2.0Hz,1H),7.14(dd,J=8.8,3.0Hz,1H).
[0090] Example 9: 6-Bromo-2-(6-chloropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0091]
[0092] The synthesis method of compound 8i is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.52(d,J=2.3Hz,1H),9.13(s,1H),8.99(dd,J=8.5,2.4Hz,1H),7.91(s,2H),7.81(d,J=8.5Hz,1H).
[0093] Example 10: 6-Bromo-2-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0094]
[0095] The synthesis method of compound 8j is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.06(s,1H),8.73–8.66(m,2H),7.86(d,J=1.2Hz,2H),7.47(t,J=8.9Hz,2H).
[0096] Example 11: 6-Chloro-2-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0097]
[0098] The synthesis method of compound 8k is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6)δ9.07–9.03(m,1H),8.69(dd,J=9.0,5.6Hz,2H),7.93(d,J=9.5Hz,1H),7.78(dd,J=9.5,2.0Hz,1H),7.47(t,J=9.0Hz,2H).
[0099] Example 12: 6-Chloro-2-(naphthalen-2-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0100]
[0101] The synthesis method of compound 81 is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.36(s,1H),9.07(s,1H),8.61(d,J=8.4Hz,1H),8.15(s,2H),8.08–7.94(m,2H),7.82(s,1H),7.65(s,2H).
[0102] Example 13: 6-Chloro-2-(furan-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0103]
[0104] The synthesis method of compound 8m is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.02(s,1H),7.95(d,J=8.7Hz,2H),7.79(d,J=8.7Hz,1H),7.64(s,1H).
[0105] Example 14: 6-Chloro-2-(1H-pyrrol-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0106]
[0107] The synthesis method of compound 8n is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ12.23(d,J=17.9Hz,1H),8.91(s,1H),7.87(d,J=1.7Hz,1H),7.82(d,J=9.5Hz,1H),7.70(d,J=9.4Hz,1H),6.77(d,J=1.7Hz,1H).
[0108] Example 15: 6-Chloro-2-(p-tolyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0109]
[0110] The synthesis method of compound 8o is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.01(d,J=1.8Hz,1H),8.52(d,J=8.2Hz,2H),7.91(d,J=9.5Hz,1H),7.77(dd,J=9.5,1.9Hz,1H),7.43(d,J=8.2Hz,2H),2.41(s,3H).
[0111] Example 16: 2-(3-bromo-4-chlorophenyl)-6-chloro-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0112]
[0113] The synthesis method of compound 8p is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ8.67(d,J=2.6Hz,1H),8.62(d,J=2.5Hz,1H),8.43(d,J=8.7Hz,1H),8.38(d,J=8.7Hz,1H),7.97(dd,J=8.7,2.4Hz,1H),7.86(dd,J=8.7,2.6Hz,1H).
[0114] Example 17: 2-(6-bromopyridin-3-yl)-6-chloro-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0115]
[0116] The synthesis method of compound 8q is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.57(d,J=1.9Hz,1H),8.93(dd,J=8.4,2.4Hz,1H),8.73(d,J=1.1Hz,1H),8.02(s,1H),7.69(d,J=8.8Hz,2H),7.58(dd,J=9.5,1.9Hz,1H).
[0117] Example 18: 6-Bromo-2-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0118]
[0119] The synthesis method of compound 8r is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.72(s,1H),8.40–8.34(m,2H),8.04–7.98(m,2H),7.07(dd,J=8.2,2.1Hz,1H),6.90(d,J=2.1Hz,1H),6.73(d,J=8.3Hz,1H).
[0120] Example 19: 6-Bromo-2-(4-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0121]
[0122] The synthesis method of compound 8s is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.07–9.03(m,1H),8.69(dd,J=9.0,5.6Hz,2H),7.93(d,J=9.5Hz,1H),7.78(dd,J=9.5,2.0Hz,1H),7.47(t,J=9.0Hz,2H).
[0123] Example 20: 6-Bromo-2-(4-bromo-3-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0124]
[0125] The synthesis method of compound 8t is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.72(s,1H),8.37(d,J=2.1Hz,1H),8.09(d,J=8.4Hz,1H),7.93(dd,J=8.5,2.2 Hz,1H),7.07(dd,J=8.3,2.1Hz,1H),6.90(d,J=2.2Hz,1H),6.71(d,J=8.3Hz,1H).
[0126] Example 21: 6-Bromo-2-(4-(methoxycarbonyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0127]
[0128] The synthesis method of compound 8u is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.63(s,1H),8.08(d,J=8.5Hz,2H),7.88(d,J=8.5Hz,2H),7.04(d,J=2.1Hz,1H),6.89(d,J=2.1Hz,1H),6.73(d,J=8.3Hz,1H),3.89(s,3H).
[0129] Example 22: 6-Bromo-2-(6-bromopyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0130]
[0131] The synthesis method of compound 8v is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.45(t,J=1.3Hz,1H),8.86(dd,J=2.4,0.8Hz,1H),8.24(dd,J=8.4,2.4Hz,1H),8.19(dd,J=8.5,0.8Hz,1H),7.88(t,J=1.6Hz,2H).
[0132] Example 23: 6-Bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0133]
[0134] The synthesis method of compound 8w is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ7.46–7.39(m,2H),7.01–6.90(m,2H),3.25(t,J=5.1Hz,4H),2.60(s,4H),2.32(s,3H).
[0135] Example 24: 7-Bromo-2-(4-cyanophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0136]
[0137] The synthesis method of compound 8x is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.64(s,1H),8.01(d,J=8.5Hz,2H),7.95–7.84(m,2H),7.05(dd,J=8.2,2.2Hz,1H),6.88(d,J=2.1Hz,1H),6.71(d,J=8.3Hz,1H).
[0138] Example 25: 6-Chloro-2-(2-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0139]
[0140] The synthesis method of compound 8y is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.10(dd,J=2.1,0.8Hz,1H),7.99(dd,J=9.5,0.8Hz,1H),7.95(dd,J=7.7,1.8Hz,1H),7.81(dd,J=9 .5,2.0Hz,1H),7.70(dd,J=8.0,1.3Hz,1H),7.63(td,J=7.7,1.8Hz,1H),7.57(td,J=7.5,1.4Hz,1H).
[0141] Example 26: 6-Chloro-2-(4-(4-methylpiperazin-1-yl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0142]
[0143] The synthesis method of compound 8z is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ10.82(s,1H),10.53(s,1H),8.00(s,1H),7.43(d,J=8.8Hz,2H),6.95(d,J=8.8Hz,2H),3.25(s,4H),2.60(s,4H),2.32(s,3H).
[0144] Example 27: 6-Bromo-2-(4-bromo-2-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0145]
[0146] The synthesis method of compound 8aa is the same as that of compound 8a; 1 H NMR (400 MHz, DMSO-d 6 )δ8.49(d,J=1.8Hz,2H),7.97(dd,J=8.2,1.9Hz,2H),7.79(d,J=8.2Hz,2H).
[0147] Example 28: 2-(5-(4-chlorophenyl)furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0148]
[0149] The synthesis method of compound 8ab is the same as that of compound 8a; 1 H NMR(400MHz,Chloroform-d)δ8.68(dt,J=6.9,1.2Hz,1H),7.88(d,J=3.7Hz,1H),7.83–7.75(m ,3H),7.64–7.57(m,1H),7.44–7.38(m,2H),7.24(dd,J=6.9,1.1Hz,1H),6.92(d,J=3.7Hz,1H).
[0150] Example 29: 2-(6-bromopyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0151]
[0152] The synthesis method of compound 8ac is the same as that of compound 8a; 1 H NMR (400MHz, Chloroform-d) δ9.61 (d, J=2.5Hz, 1H), 8.96 (dd, J=8.4, 2.4Hz, 1H), 8.70 (dt, J=7.0, 1.2Hz, 1H), 7.76 (dt, J= 9.1,1.1Hz,1H),7.69(dd,J=8.4,0.7Hz,1H),7.64(ddd,J=9.1,6.9,1.3Hz,1H),7.28(d,J=1.2Hz,0H),7.26–7.21(m,1H).
[0153] Example 30: 2-(4-bromophenyl)-6-fluoro-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0154]
[0155] The synthesis method of compound 8ad is the same as that of compound 8a; 1 H NMR (400MHz, Chloroform-d) δ8.65(dt,J=3.0,1.5Hz,1H),8.61–8.55(m,2H),7.74–7.66(m,3H),7.50(ddd,J=9.9,7.7,2.4Hz,1H).
[0156] Example 31: 2-(4-bromophenyl)-6-methyl-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0157]
[0158] The synthesis method of compound 8ae is the same as that of compound 8a; 1 H NMR(400MHz,Chloroform-d)δ8.63–8.58(m,2H),8.50–8.47(m,1H),7.71–7.66( m,2H),7.61(d,J=9.1Hz,1H),7.43(dd,J=9.2,1.7Hz,1H),2.51(d,J=1.1Hz,3H).
[0159] Example 32: 2-(4-bromophenyl)-6-cyano-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0160]
[0161] The synthesis method of compound 8af is the same as that of compound 8a; 1 H NMR (400MHz, Chloroform-d) δ8.61–8.56(m,2H),8.54(dd,J=7.2,0.8Hz,1H),7.88(dd,J=1.9,0.8Hz,1H),7.72–7.67(m,2H),7.29(dd,J=7.2,1.8Hz,1H).
[0162] Example 33: 2-(4-bromophenyl)-6-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0163]
[0164] The synthesis method of compound 8ag is the same as that of compound 8a; 1H NMR (400MHz, Chloroform-d) δ8.77(dd,J=7.2,1.0Hz,1H),8.62–8.57(m,2H),8.05(t,J=1.3Hz,1H),7.76–7.69(m,2H),7.32(dd,J=7.1,1.6Hz,1H).
[0165] Example 34: 7-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0166]
[0167] The synthesis method of compound 8ah is the same as that of compound 8a; 1 H NMR (400MHz, Chloroform-d) δ8.61–8.55(m,2H),8.54(dd,J=7.3,0.8Hz,1H),7.89–7.86(m,1H),7.73–7.65(m,2H),7.29(dd,J=7.3,1.8Hz,1H).
[0168] Example 35: 2-(4-bromophenyl)-7-chloro-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0169]
[0170] The synthesis method of compound 8ai is the same as that of compound 8a; 1 H NMR (400MHz, Chloroform-d) δ8.64–8.52(m,3H),7.73–7.66(m,3H),7.17(ddd,J=7.3,2.1,1.1Hz,1H).
[0171] Example 36: 2-(4-bromophenyl)-7-fluoro-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0172]
[0173] The synthesis method of compound 8aj is the same as that of compound 8a; 1 H NMR(400MHz,Chloroform-d)δ8.67(ddd,J=7.6,5.1,0.7Hz,1H),8.61–8.55(m,2H) ,7.73–7.67(m,2H),7.35(ddd,J=8.3,2.5,0.7Hz,1H),7.06(td,J=7.3,2.4Hz,1H).
[0174] Example 37: 8-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0175]
[0176] The synthesis method of compound 8ak is the same as that of compound 8a; 1 H NMR (400MHz, Chloroform-d) δ8.42–8.34(m,2H),7.85(d,J=7.8Hz,1H),7.82–7.77(m,1H),7.74(d,J=7.9Hz,1H),7.53(d,J=7.8Hz,1H).
[0177] Example 38: 5-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine 3-nitrogen oxide
[0178]
[0179] The synthesis method of compound 8al is the same as that of compound 8a; 1 H NMR (400MHz, Chloroform-d) δ8.71–8.62(m,3H),7.81(dd,J=7.5,1.1Hz,1H),7.74–7.66(m,2H),7.10(t,J=7.2Hz,1H).
[0180] Example 39: 6-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0181]
[0182] The first step: 2-amino-5-bromopyridine (1 eq) was dissolved in anhydrous DMF, stirred at 0°C, sodium hydride (1.2 eq) was added in batches, and the reaction was carried out at 0°C for 30 min. 4-bromobenzonitrile (1.2 eq) was added to the reaction, and the reaction was moved to room temperature for overnight reaction. TLC detection was performed. After the reaction was complete, a large amount of water was added, and ethyl acetate was extracted three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was separated by column chromatography to obtain the target intermediate, i.e., 4-bromo-N-(5-bromopyridin-2-yl)benzimine.
[0183] Step 2: Potassium iodide (1.5 eq) and iodine (1.2 eq) were dissolved in dimethyl sulfoxide, stirred at room temperature for 20 min, 4-bromo-N-(5-bromopyridin-2-yl)benzimine (1 eq) was added, followed by potassium carbonate (3 eq), the reaction temperature was raised to 100°C, the reaction was carried out for 4 h, and TLC was performed. After the reaction was complete, the reaction was cooled to room temperature, a large amount of saturated sodium thiosulfate solution was added, and the mixture was extracted with ethyl acetate (three times), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated, and the residue was separated by column chromatography to obtain the final product, i.e., 6-bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine. 1 H NMR (400 MHz, DMSO-d 6 )δ9.43(s,1H),8.12(d,J=8.3Hz,2H),7.86(s,2H),7.76(d,J=8.3Hz,2H).
[0184] Example 40: 2-(Pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridine
[0185]
[0186] The synthesis method of compound 12b is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.05(dd,J=6.8,1.2Hz,1H),8.80–8.75(m,2H),8.16–8.08(m,2H),7.94(dd,J =8.9,1.2Hz,1H),7.75(ddd,J=8.7,7.0,1.2Hz,1H),7.29(td,J=6.9,1.3Hz,1H).
[0187] Example 41: 6-Bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine
[0188]
[0189] The synthesis method of compound 12c is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.42(s,1H),8.20(dd,J=7.6,1.9Hz,2H),7.85(d,J=1.6Hz,2H),7.59–7.52(m,3H).
[0190] Example 42: 6-Bromo-2-(4-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0191]
[0192] The synthesis method of compound 12d is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.46(s,1H),8.38(d,J=7.8Hz,2H),7.94–7.87(m,4H).
[0193] Example 43: 6-Bromo-2-(2-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0194]
[0195] The synthesis method of compound 12e is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.48(s,1H),7.90(dd,J=14.7,9.8Hz,3H),7.82(d,J=7.9Hz,1H),7.55(t,J=7.4Hz,1H),7.47(t,J=7.3Hz,1H).
[0196] Example 44: 6-Bromo-2-(3-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0197]
[0198] The synthesis method of compound 12f is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.44(s,1H),8.30(d,J=1.6Hz,1H),8.18(d,J=7.8Hz,1H),7.87(d,J=1.2Hz,2H),7.74(d,J=8.1Hz,1H),7.53(t,J=7.9Hz,1H).
[0199] Example 45: 7-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0200]
[0201] The synthesis method of compound 12g is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6)δ9.43(s,1H),8.12(d,J=8.3Hz,2H),7.86(s,2H),7.76(d,J=8.3Hz,2H).
[0202] Example 46: 8-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0203]
[0204] The synthesis method of compound 12h is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.03(d,J=6.8Hz,1H),8.15(d,J=8.5Hz,2H),8.04(d,J=7.5Hz,1H),7.77(d,J=8.5Hz,2H),7.17(t,J=7.2Hz,1H).
[0205] Example 47: 5-Bromo-2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0206]
[0207] The synthesis method of compound 12i is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ8.16(d,J=8.5Hz,2H),7.92(dd,J=8.0,1.8Hz,1H),7.77(d,J=8.5Hz,2H),7.64(dd,J=12.7,4.7Hz,2H).
[0208] Example 48: 6-Bromo-2-(p-tolyl)-[1,2,4]triazolo[1,5-a]pyridine
[0209]
[0210] The synthesis method of compound 12j is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.39(s,1H),8.08(d,J=7.9Hz,2H),7.82(d,J=1.0Hz,2H),7.35(d,J=8.0Hz,2H),2.38(s,3H).
[0211] Example 49: 6-Fluoro-2-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0212]
[0213] The synthesis method of compound 12k is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.35(ddd,J=4.1,2.5,0.8Hz,1H),8.25–8.19(m,2H),7.96–7.91(m,1H),7.82(ddd,J=9.9,8.5,2.4Hz,1H),7.41–7.35(m,2H).
[0214] Example 50: 2-(4-bromophenyl)-6-fluoro-[1,2,4]triazolo[1,5-a]pyridine
[0215]
[0216] The synthesis method of compound 121 is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.36(s,1H),8.13(dd,J=10.5,8.5Hz,3H),7.79–7.71(m,3H).
[0217] Example 51: 2-(4-bromophenyl)-[1,2,4]triazolo[1,5-b]isoquinoline
[0218]
[0219] The synthesis method of compound 12m is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.08(s,1H),8.16(d,J=8.4Hz,2H),8.05(d,J=8.1Hz,1H),7.99(d,J=8.6 Hz,1H),7.79(t,J=7.7Hz,1H),7.72(d,J=8.5Hz,2H),7.55(t,J=7.5Hz,1H).
[0220] Example 52: 2-(4-bromophenyl)-6-methyl-[1,2,4]triazolo[1,5-a]pyridine
[0221]
[0222] The synthesis method of compound 12n is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6)δ8.81(s,1H),8.10(d,J=8.4Hz,2H),7.74(dd,J=13.9,8.8Hz,3H),7.55(d,J=9.1Hz,1H),2.37(s,3H).
[0223] Example 53: 2-(4-bromophenyl)-[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile
[0224]
[0225] The synthesis method of compound 12o is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.88(s,1H),8.15(d,J=8.4Hz,2H),8.01(d,J=4.9Hz,2H),7.78(d,J=8.4Hz,2H).
[0226] Example 54: 2-(4-bromophenyl)-6-phenyl-[1,2,4]triazolo[1,5-a]pyridine
[0227]
[0228] The synthesis method of compound 12p is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.34(s,1H),8.15(d,J=8.4Hz,2H),8.07(d,J=9.3Hz,1H),7.95(d,J=9.2Hz,1H),7.8 3(d,J=7.5Hz,2H),7.76(d,J=8.4Hz,2H),7.53(t,J=7.5Hz,2H),7.44(t,J=7.3Hz,1H).
[0229] Example 55: 6-Bromo-2-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0230]
[0231] The synthesis method of compound 12q is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ8.41(d,J=2.1Hz,1H),7.93(dd,J=8.9,2.5Hz,1H),7.74(d,J=8.9Hz,2H),7.58(d,J=8.9Hz,2H),7.12(d,J=8.9Hz,1H).
[0232] Example 56: 6-Bromo-2-(4-chlorophenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0233]
[0234] The synthesis method of compound 12r is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.40(s,1H),8.17(d,J=8.4Hz,2H),7.84(s,2H),7.60(d,J=8.5Hz,2H).
[0235] Example 57: 2-(4-bromophenyl)-6-chloro-[1,2,4]triazolo[1,5-a]pyridine
[0236]
[0237] The synthesis method of compound 12s is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.36(d,J=1.0Hz,1H),8.11(d,J=8.4Hz,2H),7.91(d,J=9.5Hz,1H),7.75(d,J=8.6Hz,3H).
[0238] Example 58: 2-(4-(Trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridine
[0239]
[0240] The synthesis method of compound 12t is the same as that of compound 12a; 1 H NMR (400 MHz, DMSO-d 6 )δ9.03(dd,J=6.8,1.2Hz,1H),8.42(d,J=8.1Hz,2H),7.92(dd,J=8.9,1.3Hz,3H),7.74(ddd,J=8.7,7.0,1.3Hz,1H),7.27(td,J=6.9,1.3Hz,1H)
[0241] Example 59: Experimental study on the agonistic effect of the compounds of the present invention on the AHR pathway in human cells
[0242] 1) In this experiment, based on HepG2-Lucia TMAhR cells (purchased from InvivoGen) are derived from the human HepG2 hepatoma cell line. The cells express and secrete Lucia luciferase under the control of a minimal promoter coupled to the entire regulatory sequence of the human CYP1A1 gene, which contains six dioxin response elements (DREs). TM or QUANTI-Luc TM The AhR genomic signaling pathway can be studied by monitoring Lucia luciferase activity in cell culture supernatants when using the Gold assay. This method was used to test the agonist effects of a series of compounds in human cell lines.
[0243] 2) Experimental method: HepG2-Lucia TM AhR cells were collected at 1×10 5 The cells were plated at a density of 1 μmol / mL in a 96-well plate and grown for 24 h in the absence (negative control) or presence of serially diluted test compounds (typical dilutions: 169 pmol / L, 0.5 nmol / L, 1.5 nmol / L; 4.6 nmol / L, 13.7 nmol / L, 41 nmol / L, 123 nmol / L, 370 nmol / L, 1.1 μmol / L, 3.3 μmol / L and 10 μmol / L, in triplicate).
[0244] By QUANTI-Luc TM The luciferase assay system (InvivoGen, rep-qlc1) was used to measure the activity of Lucia luciferase. That is, after 24 hours, 20 μL of supernatant was aspirated into a white flat-bottom 96-well plate, and the white plate was placed in the Glo-Max microplate reader. The time interval from sample addition to detection in each well was set to 4 seconds, and the detection was 1 second. The automatic sample addition device of the instrument added 50 μL of Lucia luciferase substrate to each well in turn, and the corresponding fluorescence value was measured. The fluorescence value of the drug-added group was compared with that of the control group to calculate the drug effect.
[0245] 3) Experimental results:
[0246] Table 1 AHR-Luc human agonist EC of the compounds of the present invention 50 value
[0247] Example <![CDATA[EC 50 (nM)]]> Example <![CDATA[EC 50 (nM)]]> Example <![CDATA[EC 50 (nM)]]> 8a >10000 8u >10000 12c >10000 8b 4660 8v >10000 12d 0.44 8c 2500 8w >10000 12e 2430 8d 43.9 8x 177 12f 9.60 8e 0.27 8y >1000 12g 625 8f 0.34 8z >1000 12h 172 8g 2.9 8aa >1000 12i 625 8h >10000 8ab >10000 12j 1895 8i >10000 8ac >10000 12k 589 8j 16.37 8ad 1093±129 12l 658 8k 61.7 8ae 842±81 12m >10000 8l 226.8 8af 77±1 12n >10000 8m 401.7 8ag 759±194 12o 23 8n 507.7 8ah 62±2 12p >10000 8o 3300 8ai 271±62 12q 1185 8p 378 8aj 83±2 12r 0.83 8q >10000 8ak 374±96 12s 156 8r >10000 8al 205±25 12t >10000 8s 17.7 12a 0.03 8t 75.4 12b 1660
[0248] The experimental results show that among the series of compounds provided by the present invention, such as compounds 8e, 8f, 12a, 12d, and 12r, the AHR signaling pathway is better stimulated in human cells, among which compound 12a has the most significant effect. The following experiments take compound 12a as the main research object.
[0249] Example 60: Luciferase reporter gene system activity detection test
[0250] HepG2-Lucia TM AhR reporter cells (InvivoGen) were used for activity screening. The cells are controlled by a minimal promoter in tandem with the complete regulatory sequence of the human CYP1A1 gene (including 6 DREs) and stably express the secreted Lucia luciferase reporter gene. TM (InvivoGen) can detect and quantify Lucia luciferase reporter protein in cell culture supernatant.
[0251] HepG2-Lucia TM AhR reporter cells were expressed at 1×10 5 The cells were inoculated at a density of 100 cells / ml in a 96-well plate. After the cells adhered to the wall, different concentrations of 12a solution were added to set up a negative control group (DMSO) and a positive control group (Tapinarof). After 24 hours of drug action, QUANTI-Luc TM The luminescence signal value was converted into a ratio to the luminescence signal of the DMSO group, i.e., a multiple, and a concentration-multiple dependence saturation curve was drawn, such as Figure 1 As shown, the EC of 12a was obtained 50 The value is 0.03nM, which is much more active than the positive drug benzenemod.
[0252] Example 61: Compound 12a regulates CYP1A1 transcription in HaCaT cells
[0253] Human immortalized epidermal cells (HaCaT) are commonly used cells for psoriasis research, in which AhR protein is highly abundant. HaCaT cells were inoculated in a six-well plate at an appropriate concentration. After the cells adhered to the wall, different concentrations of 12a solution were given, and a negative control group (DMSO) and a positive control group (Tapinarof) were set up. After 48 hours of drug action, total RNA was extracted and quantified. After reverse transcription of RNA samples with consistent concentrations, qRT-PCR experiments were performed using appropriate probe primers and SYBR dyes. Figure 2 As shown, compound 12a could induce the transcription of CYP1A1 gene in a dose-dependent manner.
[0254] Example 62: Compound 12a induces the enrichment of AhR in the nucleus
[0255] After AhR binds to its ligand, it will be transferred from the cytoplasm to the nucleus, thereby inducing downstream gene transcription. HaCaT cells were inoculated in a cell culture dish with a diameter of 100 mm at an appropriate concentration. After the cells adhered to the wall, different concentrations of 12a solution were added. After drug treatment for 1 hour, the nuclear and cytoplasmic protein extraction and separation kit (NE-PER Nuclear and Cytoplasmic Extraction Reagents, Thermol, China) was used for separation and quantification. After obtaining the same concentration of nuclear and cytoplasmic protein samples, immunoblotting analysis was performed. Figure 3 As shown, 12a at a concentration as low as 0.01 μM can still induce AhR enrichment in the cell nucleus.
[0256] Example 63: Anti-psoriasis evaluation of compound 12a
[0257] BalB / C mice (female, 20-22 g) were shaved on the back and 62.5 mg of 5% imiquimod cream was applied continuously to induce a mouse psoriasis model. Compound 12a was administered topically or orally during the period to evaluate its anti-psoriatic efficacy. Figure 4 and 5 As shown, compound 12a can achieve good anti-psoriasis effects when applied externally or orally.
[0258] Example 64: Testing of the bioavailability of compound 12a
[0259] 1) Experimental method: Compound 12a was prepared into a solution, and the solvent was 10% DMSO+45% PEG 400+5% Poloxamer F188+40% saline.
[0260] Male SD rats, 5-6 weeks, weighing 150-200g. Six SD rats were randomly divided into two groups, an oral administration group (10mg / kg) and an intravenous injection group (2.5mg / kg). Fast for 12h before administration, weigh, and calculate the dosage based on body weight. Oral administration by intravenous injection or gavage. At 9 time points after administration (0.083h, 0.25h, 0.5h, 1h, 2h, 4h, 6h, 8h, 24h), blood was collected from the submandibular vein or other suitable veins. About 0.2mL of each sample was collected, anticoagulated with sodium heparin, placed on ice after collection, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 6800g, 6 minutes, 2-8°C). Plasma samples were analyzed using LC-MS.
[0261] 2) Experimental results: The bioavailability of compound 12a in rats was 15.14%.
[0262] Table 2 Bioavailability of compound 12a in rats
[0263]
[0264]
Claims
1. A compound or a pharmaceutically acceptable salt thereof, characterized in that: The structure is:
2. Use of nitrogen oxide or a pharmaceutically acceptable salt thereof, compound II or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition in the preparation of an AHR agonist, characterized in that: The nitrogen oxide structure is as follows: The structure of compound II is as follows: The pharmaceutical composition is composed of the nitrogen oxide or a pharmaceutically acceptable salt thereof, the compound II or a pharmaceutically acceptable salt thereof as active ingredients, and pharmaceutically acceptable auxiliary ingredients.
3. The use according to claim 2, characterized in that: The AHR agonist is a drug for treating psoriasis.
Citation Information
Cited By
Use of a caesalpinia extract in the preparation of a medicament for the treatment of psoriasis
CN119055695B
